Yang, Z. et al. (57) found that IL-33 treatment promoted the lung cancer cell migration as well as invasion and increased the expression of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) in a ST2-dependent manner. This evidence concerns the gene IL1RL1 and lung carcinoma.